Search Results - CLINICAL PHARMACOKINETICS PHARMACOGENOMICS
-
1
Impact of Pharmacogenomics in Clinical Practice
Published in Pharmaceuticals (2023-11-01)“…Moreover, reasons for poor implementation of pharmacogenomics in everyday clinical settings are discussed. …”
Get full text
Article -
2
Current clinical evidence on pioglitazone pharmacogenomics
Published in Frontiers in Pharmacology (2013-11-01)“…In this hypothesis article, the current clinical evidence on pioglitazone pharmacogenomics is summarized and related to variability in pioglitazone response. …”
Get full text
Article -
3
Antifungals: From Pharmacokinetics to Clinical Practice
Published in Antibiotics (2023-05-01)“…In this review, we performed an overview of the history of antifungals and their classification, mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) characteristics and clinical applications. …”
Get full text
Article -
4
Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art Review
Published in Drug Design, Development and Therapy (2025-08-01)“…Therefore, larger-scale, global, multi-centre clinical trials are needed in the future to validate potential gene loci for testing.Keywords: rivaroxaban, pharmacogenomics, pharmacokinetics, bleeding events, polymorphism, variant…”
Get full text
Article -
5
Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation
Published in Journal of Pharmaceutical Health Care and Sciences (2025-06-01)“…In this study a population pharmacokinetic and pharmacogenomic analysis was conducted to clarify covariate factors affecting the edoxaban pharmacokinetics in Japanese adult AF patients. …”
Get full text
Article -
6
-
7
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study
Published in npj Breast Cancer (2024-09-01)“…This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib in self-identified Black women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer. …”
Get full text
Article -
8
Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients
Published in Pharmaceutics (2010-09-01)“…This paper examines available literature in an attempt to summarize the potential pharmacokinetic and pharmacogenomic variability that exists between the two populations.…”
Get full text
Article -
9
-
10
454 Factors influencing pharmacokinetics of tacrolimus in hematopoietic stem cell transplantation: The integration of microbiome and pharmacogenomics
Published in Journal of Clinical and Translational Science (2025-04-01)“…Our objective is to determine a microbiome signature that influences oral TAC pharmacokinetic (PK) and to develop a clinical tool to select the TAC dose. …”
Get full text
Article -
11
Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature
Published in Pharmaceutics (2024-08-01)“…These observations underscore the need for large-scale, controlled pharmacogenomics studies focusing on a broad panel of genes involved into MDMA pharmacokinetics and PD. …”
Get full text
Article -
12
-
13
Editorial: Editor’s feature: negative findings in pharmacogenetics and pharmacogenomics
Published in Frontiers in Pharmacology (2023-08-01)Get full text
Article -
14
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined si...
Published in Drug Design, Development and Therapy (2017-11-01)“…Additionally, MB12066 was mainly eliminated through metabolism in humans.Keywords: pharmacokinetics, Phase I, first-in-human, NQO1, pharmacogenomics …”
Get full text
Article -
15
Editorial: Editor’s feature: negative findings in pharmacogenetics and pharmacogenomics volume II
Published in Frontiers in Pharmacology (2025-07-01)Get full text
Article -
16
Genetic variation in alcoholism and opioid addiction susceptibility and treatment: a pharmacogenomic approach
Published in AIMS Molecular Science (2021-10-01)“…The neurobiology of addiction involves innumerate genes with combinatorial and epistatic interactions, creating a difficult landscape for concrete conclusions. In contrast, pharmacogenomic variation in the treatment of alcoholism yields more immediate clinical utility, while also emphasizing pathways crucial to the progression of addiction. …”
Get full text
Article -
17
Assessment of pharmacogenomic agreement [version 1; referees: 3 approved]
Published in F1000Research (2016-05-01)Get full text
Article -
18
A Bayesian Approach for Population Pharmacokinetic Modeling of Alcohol in Japanese Individuals
Published in Current Therapeutic Research (2017-01-01)Get full text
Article -
19
Pharmacokinetics and lipid-lowering efficacy affected by polymorphisms in genetic variability in statin therapy
Published in Egyptian Journal of Medical Human Genetics (2025-09-01)“…Consequently, there is growing scientific interest in identifying genetic polymorphisms in enzymes and transporters involved in the pharmacokinetic pathways of statins. This review discusses clinically important genetic polymorphisms of statin metabolism and transport and their potential impact on treatment outcomes based on the patient’s genetic profile. …”
Get full text
Article -
20
Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications
Published in Frontiers in Pharmacology (2025-08-01)“…This review explored the pharmacokinetics, pharmacogenomics of CYP2C9 and HLA associated with hypersensitivity reactions, immunopathogenesis and its clinical implications. …”
Get full text
Article